The core dispute between Moderna, Arbutus, and Genevant centered on LNP patents. As the dominant delivery system for current mRNA technology, LNP patent issues directly shape the development trajectory of the entire mRNA field. Core patents for this system are held by only a handful of companies.

Arbutus owns foundational patents covering LNP composition, structure, and manufacturing methods, including classic cationic lipid structures and lipid types. Genevant is a joint venture between Arbutus and Roivant Sciences; Arbutus licensed its LNP patents to Genevant, and the two typically act as a unified interest group in patent disputes.

A key technical employee from Tekmira (Arbutus’ predecessor) left to found Acuitas, obtained an LNP patent license from Arbutus, and then assigned these licenses to Moderna in 2015. Arbutus challenged this transfer. After a series of disputes, the license to Acuitas was terminated in 2018, but partial sublicenses to Moderna were retained—laying the groundwork for the subsequent patent war.

Beginning around 2018, Moderna attempted to invalidate two of Arbutus’ patents without success. In December 2021, the U.S. Court of Appeals for the Federal Circuit rejected Moderna’s petition. In February of the following year, Arbutus and Genevant formally sued Moderna, alleging infringement of six patents.

Notably, the plaintiffs did not seek to halt Moderna’s vaccine sales from the start, but rather “reasonable royalties on all infringing sales”—in plain terms, a share of revenue. The lawsuit involved not only the COVID-19 vaccine Spikevax, but also Moderna’s 2024-approved respiratory syncytial virus vaccine mRESVIA, which also uses the patents.

Following the pandemic, demand for COVID-19 vaccines plummeted, and Spikevax sales collapsed. Meanwhile, commercial performance of mRESVIA has been underwhelming. Despite strong cash reserves from past Spikevax sales, the damages sought by the plaintiffs would still have been astronomical.

The trial was scheduled to begin on March 9, 2026, and would have been the first COVID-19 vaccine technology lawsuit to go to a jury trial. Less than a week before the hearing, the parties reached a settlement.

Under the agreement:

• Moderna will pay a one-time upfront payment of $950 million in Q3 2026.
• An additional **$1.3 billion** is contingent on the outcome of Moderna’s Section 1498 appeal. Moderna argues that under this provision, the U.S. government should bear liability for vaccines sold under government contracts. If the appeal prevails, the $1.3 billion will not be paid; if it loses, Moderna will pay up to $1.3 billion within 90 days of the ruling, with the exact amount depending on the scope of the decision.

The agreement also stipulates that if Moderna prevails in further litigation, Arbutus and Genevant will fully refund all paid amounts plus interest.

The settlement includes future arrangements: Genevant grants Moderna a global non-exclusive license to continue using SM-102-based LNP delivery technology in future infectious disease mRNA vaccines. Both parties promise not to sue over related patents, and Moderna will no longer challenge the validity of the plaintiffs’ patents.

Moderna CEO Stéphane Bancel stated:

“Resolving this legacy issue from the pandemic response eliminates uncertainty and allows us to fully focus on Moderna’s exciting near-term future.”

He noted the company expects over $5 billion in liquidity in 2026, a return to revenue growth in 2026, and targets break-even by 2028.

This provides greater certainty for Moderna’s pipeline: its next-generation COVID-19 vaccine mNexspike, experimental COVID-flu combination vaccine mCombriax, and broader flu vaccine programs.

However, only Moderna received the license. For later entrants, the “patent wall” remains firmly in place.

The settlement between Moderna and Arbutus is just one piece in the larger mRNA patent war puzzle. Dozens of lawsuits have been filed, involving mRNA leaders such as Moderna and BioNTech, as well as Big Pharma including Pfizer, Bayer, Johnson & Johnson, and GSK.

While its dispute with Moderna is resolved, Arbutus/Genevant’s lawsuit against Pfizer/BioNTech is still ongoing in the U.S. Pfizer/BioNTech is the world’s largest mRNA vaccine manufacturer, with Comirnaty capturing roughly two-thirds of global COVID-19 mRNA vaccine sales.

In 2023, Arbutus/Genevant sued Pfizer/BioNTech over LNP patents. In September 2025, the court issued a claim construction ruling favorable to Pfizer at a Markman hearing, but the case remains pending.

Mutual Lawsuits Between mRNA Leaders

• 2022: Moderna sued Pfizer and BioNTech for infringing its mRNA-related patents.
• February 2026: BioNTech countersued Moderna in the U.S. District Court for the District of Delaware, alleging that Moderna’s next-generation COVID-19 vaccine mNEXSPIKE infringes its low-dose vaccination technology—a key innovation in mRNA platform development.

CureVac & GSK vs. Pfizer/BioNTech

• 2022: CureVac sued Pfizer/BioNTech for mRNA patent infringement. GSK, CureVac’s mRNA vaccine partner, joined the battle.
• August 2025: CureVac and Pfizer/BioNTech settled. BioNTech agreed to pay CureVac $370 million plus a 1% sales-based royalty, and acquire CureVac to obtain its global licenses.
• BioNTech also paid $370 million to GSK, plus an additional $130 million after completing the CureVac acquisition, and equivalent sales-based royalties starting in 2025.
• Separately, GSK sued Pfizer/BioNTech in 2023; that case remains ongoing.

Bayer’s Broad Offensive

In January 2026, Bayer sued Moderna, Pfizer/BioNTech, and Johnson & Johnson in one sweep, alleging illegal use of mRNA technology patents developed by Monsanto (acquired by Bayer) in the 1980s. The patents relate to “eliminating ‘problematic’ coding sequences in cellular building blocks to improve mRNA stability and protein yield or quality.”

Bayer stated in the complaint that BioNTech “has admitted to using codon optimization in its mRNA products.” Although Johnson & Johnson’s COVID-19 vaccine is a traditional viral vector vaccine that has been discontinued, Bayer argued it still required improved mRNA stability to express proteins.

Bayer’s demands are clear:

• Profits-based damages for past infringement
• Future royalties on vaccine sales
• No request for an injunction to block sales

With Comirnaty sales exceeding $93 billion, Bayer has enormous potential upside in seeking revenue shares.

The wave of mRNA and LNP lawsuits stems from a simple reality: mRNA drugs (including vaccines) only work if safely and effectively delivered into cells. LNP is currently the only clinically validated system for large-scale in vivo mRNA delivery.

Early patent holders (e.g., Arbutus, Acuitas) discovered their core patents—especially foundational chemical structure patents—were used by later drug developers, often “inadvertently” or under low-cost licenses. The COVID-19 pandemic turned this technology into massive commercial value, creating the direct financial incentive behind the litigation wave.

After this wave of lawsuits, it is clear that mRNA drug patent portfolios—especially around LNP delivery—are highly mature, making it extremely difficult for latecomers to climb over the patent wall.

Moderna’s settlement resolved its legal risks by paying for licenses. For others still outside the wall, the path remains long.

How Latecomers Are Circumventing LNP Patents

1. New Chemical Structures

• Wisgen Bio claims to have broken existing LNP patent barriers by developing a next-generation delivery system using multi-nitrogen ionizable lipids instead of the single-nitrogen versions widely used today, optimized via a central composite design to improve targeting, safety, and storage stability.

2. Extrahepatic Targeted Delivery

• Staray Therapeutics focuses on extrahepatic targeted delivery to expand RNA drug applications. Using lipid chemistry expertise, it built a library of thousands of lipid entities, then used AI and high-throughput screening to identify tissue-specific LNPs. By conjugating antibodies and other ligands to LNP surfaces, it achieves selective delivery to specific cell subtypes.

3. AI-Driven Development

On February 23, Jingtai Holdings and Yaotang Bio announced a partnership to build an AI-driven closed-loop mRNA dry-wet lab screening platform:

• Jingtai uses AI to multi-objectively optimize mRNA sequences and generate candidates.
• Yaotang uses its LNP delivery platform for formulation and validation, feeding data back to the AI model for further optimization.

Yaotang’s LNP expertise also lays the foundation for future in vivo mRNA-based CAR-T therapies, which could drastically reduce the cost of traditional CAR-T treatments.

4. Alternative Delivery Systems

Beyond LNP, emerging platforms are being developed for differentiation in targeting, safety, and cost:

• Peptide Nanoparticles (PNP): Sirnaomics’ PNP platform uses biodegradable peptides with theoretically lower toxicity, suitable for both siRNA and mRNA delivery.
• Extracellular Vesicles (EVs): While academically popular, few companies have mature EV-mRNA delivery platforms. Industrialization faces three major hurdles:
  • Low loading efficiency
  • Difficult large-scale production
  • Uncontrollable heterogeneity

The patent wall is high, but not impenetrable. Through chemical iteration, AI-enabled screening, and delivery vector innovation, latecomers are finding breakthroughs. Technological evolution never stops.

mRNA vaccines rose to fame overnight, lifting BioNTech and Moderna to industry leadership. The mRNA sector boomed. But as the capital winter arrived, most projects quietly exited—followed by a prolonged wave of litigation.

Whether Moderna paid to “buy a ticket” or Arbutus launched lawsuits across the industry, one lesson is clear:Technical breakthroughs matter, but controlling intellectual property is the real power at the table.